Michael Cloonan is CEO & President at Sionna Therapeutics, Inc. (SION). They have made 1 open-market trade across 1 company since 2019, most recently 2026-09-17.
CIK 0001704336
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SION | SELL · 10b5-1 | 2025-10-21 | 2025-10-22 | $36.21 | $6.4M | -7.2% | +12.4% | +3.0% |
| SION | SELL · 10b5-1 | 2025-10-15 | 2025-10-17 | $31.26 | $1.6M | +16.0% | +23.5% | +20.1% |
| SION | SELL · 10b5-1 | 2025-09-26 | 2025-09-30 | $29.11 | $1.5M | +1.7% | +31.3% | +47.9% |
| SION | SELL · 10b5-1 | 2025-08-26 | 2025-08-28 | $24.97 | $1.2M | -7.4% | +16.5% | +72.8% |
| SION | SELL · 10b5-1 | 2025-08-20 | 2025-08-21 | $22.75 | $569K | +2.9% | +8.5% | +61.0% |
| SAGE | SELL | 2019-05-22 | 2019-05-24 | $175.00 | $4.4M | -0.6% | +0.9% | -3.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.